Fig. 3From: FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumaba Change in tumor SUVmean at 12 weeks differentiated patients who had progression-free survival less than or equal to the median progression-free survival time (24 weeks) from patients who had progression-free survival greater than the median. b Changes in PSA levels after 12 weeks for the same set of patients as shown in insert (a)Back to article page